Ophthalmology Perspectives Podcast
Episode 1: Patient Recruitment in Ophthalmology Trials
Topics: In this conversation today, we're going to dive into the evolving landscape of patient recruitment in ophthalmology and explore how Belite Bio and Fortrea are collaborating to overcome protocol complexities, and discuss the unique opportunities Asia PAC represents for ocular development. We'll also look ahead to the most promising trends shaping the future of ophthalmology trials.
Host: Amber Burg
Participants:
- Tanya Richardson Fortrea’s Therapeutic Strategy Head for Neuroscience and Ophthalmology
- Lisa Liang, Senior Director of Clinical Operations at Belite Bio.
Episode 2: Ophthalmology Trials at the Leeds CRU
Description: In today’s episode, we delve into the fascinating world of Phase 1 clinical research at Fortrea’s Leeds clinical research unit in the UK. We explore the operational challenges and innovative solutions behind a recent, complex ophthalmology clinical trial.
Host: Amber Burg
Participants:
- Warren Edwicker, Director of Clinic Operations at Fortrea’s Leeds CRU
- Natalie Wood, Clinical Research Associate, Leeds UK
Episode 3: Gene Therapy, Patient-Centric Operations, and Risk-Benefit Challenges in Phase 1 Ophthalmology Trials
Description: Today we explore the unique challenges and opportunities in Phase 1 ophthalmology clinical trials, focusing on gene therapy and inherited retinal diseases.
Host: Amber Burg
Participants:
- David Hoelscher, Senior Medical Director, Ophthalmology
- Sarah Bolger-Ford, PhD, Senior Delivery Director, Strategic Delivery and Growth
References:
- Goyani P, Christodoulou R, & Vassiliou E. (2024). Immunosenescence: Aging and immune system decline. Vaccines, 12(12), 1314. https://doi.org/10.3390/vaccines12121314
- Liu Y, Zong X, Cao W, Zhang W, Zhang N, & Yang N. (2024). Gene therapy for retinitis pigmentosa: Current challenges and new progress. Biomolecules, 14(8), 903. https://doi.org/10.3390/biom14080903
- Xavier de Almeida G, Ferreira Silva de Melo N, & Wiziack Zago PM. (2025). Cushings syndrome, blood glucose, and osteoporosis: Adverse effects of long-term corticosteroid use. InterAmerican Journal of Medicine and Health, 8. https://doi.org/10.31005/iajmh.v8i.242
- Jones PR, Yasoubi N, Nardini M, & Rubin GS. (2016). Feasibility of macular integrity assessment (MAIA) microperimetry in children. Investigative Ophthalmology & Visual Science, 57, 6349–6359. https://doi.org/10.1167/iovs.16-20037
- Lu Q, Wright A, & Pan ZH. (2024). AAV dose. Gene Therapy, 31, 572–579. https://doi.org/10.1038/s41434-024-00485-7
- European Medicines Agency. (2024). Luxturna: INN. EMA Luxturna Product Information
- Ghoraba HH, Akhavanrezayat A, et al. (2022). Ocular gene therapy review. Clinical Ophthalmology, 16, 1753–1771. https://doi.org/10.2147/OPTH.S364200
- Ozha S, Jagdale A, & Shinde N. (2024). Clinical and ocular inflammatory inhibitors. Microbiologica Hellenica, 69(3), 187–203. https://doi.org/10.3390/amh69030018
- Reichel FF, Seitz I, Wozar F, et al. (2023). Development of retinal atrophy after subretinal gene therapy. British Journal of Ophthalmology, 107, 1331–1335.
- Scruggs BA, Berger A, et al. (2025). Retinal gene therapy using epiretinal AAV. Science Advances. https://doi.org/10.1126/sciadv.adv7922
- World Health Organization. (2022). Global regulatory framework for cell and gene therapy products. WHO Document
- MacLaren RE. (2024). Gene therapy in early retinal degeneration. The Lancet, 404(10456), 911–913. https://doi.org/10.1016/S0140-6736(24)01853-1
- Brar AS, Parameswarappa DC, Takkar, et al. (2024). Gene therapy for inherited retinal diseases. Ophthalmology and Therapy, 13, 21–50. https://doi.org/10.1007/s40123-023-00862-2
- U.S. Food and Drug Administration. (2020). Long term follow. FDA Guidance
- European Medicines Agency. (2009). Guideline on follow. EMA Guideline